Whereas the usefulness of SGLT2 inhibitors as antidiabetic agents is now established, the role of SGLT2 inhibitors in the treatment of nondiabetic kidney disease is just emerging [15]. The gene discussed is SLC5A2; the disease is kidney disorder.